Skip to main content

Table 1 Summary of the characteristics of the studies included in the network meta-analysis

From: Respiratory support strategy in adults with acute hypoxemic respiratory failure: a systematic review and network meta-analysis

Source Total no. of patients Main reason for hypoxemic respiratory failure (main baseline risk factor) Main exposure Comparator P/F ratio (mean) Outcomes of interest assessed
Wysocki [27] 1995 41 Mixed AHRF (CAP 39.0%, CPE 34.1%) NIV (n = 21) SOT (n = 20) 207 Mortality, intubation
Antolnelli [26] 1998 64 Mixed AHRF (CPE 19%, atelectasis 25%) NIV (n = 32) IMV (n=32) 120 Mortality
Confalonieri [29] 1999 56 CAP NIV (n = 28) SOT (n = 28) 175 Mortality, intubation
Antonelli [28] 2000 40 Mixed AHRF (ARDS 37.5%, atelectasis 25%) NIV (n = 20) SOT (n = 20) NA Mortality, intubation
Delcaux [30] 2000 123 Mixed AHRF (CAP 54.5%) NIV (n = 62) SOT (n = 61) 144 Mortality, intubation
Martin [32] 2000 61 Mixed AHRF (COPD 38%) NIV (n = 32) SOT (n = 29) 199 Mortality, intubation
Hilbert [31] 2001 52 CAP in immunocompromised patients NIV (n = 26) SOT (n = 26) 139 Mortality, intubation
Ferrer [34] 2003 105 Mixed AHRF (CAP 32.4%, CPE 28.6%) NIV (n = 51) SOT (n = 54) 103 Mortality, intubation
Cosentini [33] 2010 47 CAP NIV (n = 20) SOT (n = 27) 248 Mortality, intubation
Squadrone [35] 2010 40 Mixed AHRF in immunocompromised patients NIV (n = 20) SOT (n = 20) 269 Mortality, intubation
Wermke [37] 2012 86 CAP in immunocompromised patients NIV (n = 42) SOT (n = 44) 270 Mortality, intubation
Zhan [38] 2012 40 ALI (immunocompromised 30%) NIV (n = 21) SOT (n = 19) 230 Mortality, intubation
Brambilila [36] 2014 81 CAP (immunocompromised 32%) NIV (n = 40) SOT (n = 41) 141 Mortality, intubation
Azevedo [39] 2015 30 CPE (43.3%), CAP (33.3%) NIV (n=16) HFNO (n=14) NA Intubation
Frat [12] 2015 310 Mixed ARF (CAP 63.5%) NIV (n = 110) HFNO (n = 106)
SOT (n = 94)
155 Mortality, intubation
Lamiale [40] 2015 100 Mixed AHRF in immunocompromised patients (sepsis related 50%) HFNO (n = 52) SOT (n = 48) 114 Intubation
Lemiale [41] 2015 374 Pneumonia in immunocompromised patients NIV (n = 191) SOT (n = 183) 142 Mortality, intubation
Jones [43] 2016 303 Mixed AHRF (COPD 23.9%, Pneumonia 23.8%) HFNO (n = 165) SOT (n = 138) NA Mortality, intubation
Muncharaz [42] 2017 65 Mixed AHRF (CAP 63.1%) NIV (n = 34) IMV (n = 31) 97 Mortality
Azoulay [25] 2018 776 Mixed AHRF in immunocompromised patients (Pneumonia 53.0%) HFNO (n = 388) SOT (n = 388) 132 Mortality, intubation
He [44] 2019 200 CAP NIV (n = 102) SOT (n = 98) 231 Mortality, intubation
Andino [45] 2020 46 Mixed AHRF (CAP 30%) HFNO (n = 24) SOT(n=22) 96 Mortality, intubation
AlptekİnoĞlu Mendİl [46] 2021 100 Mixed AHRF (pneumonia 74%) HFNO (n = 51) SOT(n=49) 262 Mortality, intubation
Awadallah [47] 2021 52 ARDS NIV (n = 26) IMV (n = 26) 95 Mortality
Grieco [48] 2021 109 AHRF in COVID-19 patients NIV (n = 54) HFNO (n = 55) 102 Mortality, intubation
  1. AHRF acute hypoxemic respiratory failure, ALI acute lung injury, ARDS acute respiratory distress syndrome, ARF acute respiratory failure, CAP community-acquired pneumonia, COPD chronic obstructive pulmonary disease, CPE cardiopulmonary edema, HFNO high-flow nasal oxygen, IMV invasive mechanical ventilation, NA not available, NIV noninvasive ventilation, P/F ratio ratio of arterial oxygen partial pressure to fractional inspired oxygen, SOT standard oxygen therapy